Aspire Biopharma
ASBP
13 hedge funds and large institutions have $251K invested in Aspire Biopharma in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
8% more funds holding
Funds holding: 12 → 13 (+1)
3.38% more ownership
Funds ownership: 0.25% → 3.63% (+3.4%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
33% less capital invested
Capital invested by funds: $372K → $251K (-$121K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$151K |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$103K |
| 3 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$102K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$92K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$79.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$65.1K |
| 3 |
CA
Crossingbridge Advisors
Pleasantville,
New York
|
-$8.07K |
| 4 |
Citigroup
New York
|
-$1.9K |
| 5 |
CA
Crewe Advisors
Salt Lake City,
Utah
|
-$10 |
ASBP Hedge Fund Activity: Q2 2026 in Review
13 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q2 2026, worth a combined $251K — down 33% from $372K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ASBP positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $151K. The largest seller was Morgan Stanley, exiting entirely with an estimated $79.3K sold.
- 13 institutional investors held Aspire Biopharma (ASBP) as of Q2 2026, up from 12 in Q1 2026.
- Funds reported $251K of Aspire Biopharma stock for Q2 2026, down 33% quarter-over-quarter.
- 3 funds opened new Aspire Biopharma positions in Q2 2026 and 2 closed out, a net change of +1 holder.
- The largest Aspire Biopharma buyer in Q2 2026 was Jane Street, an estimated $151K added.
- The largest Aspire Biopharma seller in Q2 2026 was Morgan Stanley, an estimated $79.3K sold.
Based on aggregated 13F filings for Q2 2026.